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Skin lesions in mycosis fungoides (MF) and cutaneous-type 
adult T-cell leukemia/lymphoma (c-ATL) are sometimes 
difficult to differentiate. Our previous investigations showed 
that the a-chain of interleukin-2 receptor (IL-2Ra) secretion 
is enhanced in both acute and chronic type A TL. This finding 
suggested increased levels of IL-2Ra in c-ATL that might 
differentiate it from MF. In this study, we report several 
observations on IL-2Ra levels in MF and c-ATL. 1) Plasma 
levels ofIL-2Ra determined by enzyme-linked immunosor-
bent assay were higher in patients with c-A TL (tumor group, 
17,571 ± 5,919 O/ml; non-tumor group, 4,546 ± 1,788 
0/ ml) than those of patients with MF (tumor group, 
2,352 ± 861 O/ml; plaque group, 530 ± 174 O/ml). 2) 
The percentages of IL-2Ra - positive cells in skin lesions of 
c-ATL were 30.5 ± 13.4% in the non-tumor group and 
62.7 ± 12.0% in the tumor group, which were significantly 
M ycosis fungoides (MF) is a cutaneous T-celllym-phoma (CTCL) that involves the skin and may progress to involve lymph nodes, blood, and vis-ceral organs [1-3] . In southwestern Japan, an en-demic area of human T-cell leukemia virus-l 
(HTL V -I) frequently associated with adult T -cell leukemia [4 - 6], 
many cases of cutaneous-type adult T-cell leukemia/lymphoma 
(c-ATL) have been reported. c-ATL is a lymphoproliferative dis-
order initially cl~aracterized by erythema, papules, and tumors in the 
skin, and sometimes progresses to involve lymph nodes, blood, and 
visceral organs [7,8]. The patients with c-ATL survive longer with 
relatively stable clinical features than those with prototypic ATL, 
which has a subacute or acute course [9,10]. T he clinical features of 
the patients with c-ATL are very similar to those of MF. Thus, it is 
difficult to distinguish c-ATL from MF even when they involve 
other organs at advanced stages unless the clinical course is followed 
for a long time. 
The human interleukin-2 receptor (IL-2R) is known to be com-
posed of at least two different IL-2-binding peptides: a 50- to 
55-kDa molecule referred to as the a-chain (IL-2Ra) and a 70- to 
75-kDa molecule referred to as the p-chain (IL-2RP) [11-14]. By 
using specific antibodies binding to the IL-2Ra peptide or IL-2RP 
peptide, a quantitative enzyme-linked immunosorbent assay 
(ELISA) was devised to measure soluble forms ofIL-2Ra [15,16] or 
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adult T-cell leukemia/ lymphoma; MF, mycosis fungoides. 
higher than those of MF, plaque group (12.7 ± 5.9%), and 
tumor group (3.4 ± 2.3%).3) Further, there was a significant 
correlation between plasma IL-2Ra levels and the number of 
IL-2Ra - positive cells in skin lesions in patients with c-ATL 
(r = 0.654, P < 0.0001) and MF (r = 0.537, P < 0.01) on an 
individual basis; whereas no increased IL-2Ra levels in pe-
ripheral blood mononuclear cells were observed in patients 
with either MF or c-ATL. 4) Skin lesions of c-ATL had much 
higher levels of IL-2Ra genomic RNA than those of MF in 
their initial stages when measured by DNase/reverse tran-
scription/polymerase chain reaction and liquid hybridization 
analysis. These findings suggest that increased plasma IL-
2Ra levels in patients with either MF or c-ATL may be 
linked to cellular IL-2Ra levels in the skin lesions, and thus 
reflect the difference between MF and c-ATL.] lIwest Derma-
tol 102:710- 715, 1994 
IL-2RP [17] in culture supernatants of activated T cells, B cells, 
macrophages, and HTL V -I - infected cells il1llitro [18 - 20] . Further, 
elevated levels of soluble IL-2Ra were also detected in plasma of 
patients with acute- and chronic-type ATL [18,19]' AIDS [21], or 
various immune disorders in the state of lymphocyte activation. In 
ATL, the plasma IL-2Ra levels were highly correlated with disease 
activity and also with sIL-2Ra levels in culture supernatants of 
peripheral blood mononuclear cells (PBMC), suggesting that the 
marked increase in plasma IL-2Ra levels may originate from 
HTLV-I-infected cells that overexpressed IL-2Ra on their cell 
surface. In this study, we demonstrated a difference in IL-2Ra levels 
in patients with MF and c-ATL. The plasma levels were signifi-
cantly correlated with the levels ofIL-2Ra in skin lesions examined 
immunohistochemically. Interestingly, both the plasma and ge-
nomic RNA levels significantly reflected the difference in IL-2Ra 
levels between c-ATL and MF, suggesting that both are useful im-
munologic parameters. to distinguish c-ATL from MF in their early 
stages. 
MATERIALS AND METHODS 
Patients and Normal Controls Twenty-three patients (17 men and 6 
women) with MF [l,21J including two with erythema lesions, 11 with 
plaque lesions, and 10 with skin-tumor lesions were followed in the Depart-
ment of Dermatology at Kumamoto University Hospital and selected for 
study. Their ages ranged from 32 to 71 yea.rs (median, 48 years). Twenty-
seven patients (15 men and 12 women) diagnosed as having c-ATL [7,8] 
including 17 with non-tumot lesions and 10 with tumor lesions were also 
followed in the same department for periods of 0 to 10 years. Their ages of 
cATL patients ranged from 34 to 77 years (median, 59 years). Seventeen of 
27 patients with cATL have shown lesions limited to skins. The other 10 of 
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Figure 1. Plasma IL-2Ra levels in patients with different groups of skin 
lesions (nontumor group or tumor group) of MF or c-ATL. Receptor levels 
of plasma were determined by IL-2Ra ELISA with a calculated sensitivity of 
100 V/m!. Levels were higher in both groups of patients with cATL than 
the MF groups. Plasma from nontumor group of MF (n = 13) had IL-2Ra 
levels of 530, which was similar to the plasma levels of healthy normal 
controls (n = 50, 498 ± 346, data not shown) or ATLA-positive asympto-
matic carriers (n = 35,597 ± 473, data not shown). Grouped plots using 
dots that reveal the distribution of plasma IL-2Ra value of each patient 
grouped were overlaid on their notched box-whisker plots [39] . 
27 cA TL patients have skin lesions with infiltrations to blood (ATL cells, 0.1 
to 5.0%) and/or to lymph nodes. All patients with the diagnosis of MF or 
c-ATL were further investigated by bone-marrow examination and lymph-
node biopsy. Proviral DNA of HTLV-I was detected by HTLV-I Southern 
blot analysis using genomic DNA of both PBMC, and skin samples [9]. 
Thirty-five seropositive carriers of antibodies against ATL-associated anti-
gens (A TLA) were used as controls. Fifty A TLA-negative blood donors were 
also used as normal controls. 
Studies of Skin Lesions Biopsy specimens were taken from skin lesions 
of all patients, and the specimens were frozen in tl-hexane at -78 ° C, and 
stored at -78 ° C until sectioning. Cryostat sections were cut to a thickness of 
5 pm and air-dried. Optimal concentrations of anti-IL-2Ra monoclonal 
antibody (Becton Dickinson and Co., San Jose, CAl were predetermined by 
titration assays. The avidin-biotin-peroxidase complex method was used for 
amplification of staining using diaminobenzidine. Methylgreen was used for 
counter staining. The number of infiltrating cells and IL-2Ra- positive cells 
in skin lesions was expressed as the total of 15 strips, which represents the 
mean of the three sections counted, according to the method of Kay [23], as 
described previously [24]. IL-2Ra levels were expressed as the ratio of the 
percent of positive cells to the absolute number of cells. 
Preparation of Plasma and Cell Extract PBMC and plasma were pre-
pared from heparinized blood as described previously [16,20]. The cells were 
washed with Tris-buffered saline and lysed with a buffer containing 
150 roM NaCl, 50 mM Tris-HCl, pH 7.2, 0.5% Nonidet P-40, 0.1% Tri-
tonX-100, 0.5% sodium deoxycholate, 0.1 % SDS, with 1 % Trasilol (Sigma 
Chemical Co., St. Louis, MO) and 2 roM phenylmethylsulfonyl fluoride 
(Sigma) for 30 min at 4°C. Then the suspension was centrifuged at 
10,000 X g for 30 min to remove the nuclear fraction. 
Assay Procedure for Human sIL-2Ra The ELISA method used to 
quantify IL-2Ra was the fluorescence sandwich (FS)-ELISA for human 
IL-2Ra described previously [16,21]. In brief, this ELISA used two mono-
clonal antibodies, H48 and HA26 [25], that reacted specifically with differ-
ent epitopes on the human IL-2Ra molecule. The results were expressed in 
arbitrary units based on a reference curve as previously described. All samples 
of plasma and cell extracts were tested after storage at -78 ° C. 
Polymerase Chain Reaction (PCR) for the Detection ofIL-2Ra: Ge-
nomic RNA Total RNA was prepared from biopsy sfecimens from skin 
lesions by the method of Chomczynski and Sacchi [26 . Treatment of the 
genomic RNA with RNase-free DNase and its reverse transcription (RT) 
was performed by a modification of the method of Ottman et al [27] using 
the 20 pmol of the 3' primer of human IL-2Ra: (Clontech Laboratories, Inc., 
Palo Alto, CAl. Both RTand non-RT genomic DNA was amplified by PCR 
as follows. Final reaction conditions were 10 roM Tris-HCI (pH 8.3), 
50 roM KCl, 1.5 roM MgCl2 , 0.01 % (w Iv) gelatin, 20 pmol each of dNTP, 
50 pmol of 5' and 3' primers (Clontech), and 2.5 units ofTaq polymerase 
(Perkin-Elmer Cetus, Norwalk, CT) in a total volume of 100 II!. Samples 
were amplified by 40 cycles in a Perkin-Elmer Cetus DNA Thermal Cycler: 
template denaturation, 1 min at 94 ° C; primer annealing, 2 min at 55 ° C; and 
DNA synthesis by the Taq polymerase, 2 min at 72°C. PCR products were 
analyzed by liquid hybridization with an end-labeled IL-2Ra: DNA probe 
followed by 15% polyacrylamide gel electrophoresis [28]. The following 
sequence of IL-2Ra was selected and synthesized as the probe for PCR; 
5' - ATTATCAGTGCGTCCAGGGATACAGGGCTCTACACAGAG - 3' 
(positions 383-421). As control of DNase/RT /PCR of genomic RNA, a 
1,000 base pair fragment of human p-globin RNA were amplified by the 
DNase/RT/PCR method using p-actin primer pair (Clontech). 
A standard curve was generated with the genomic RNA from MT-2 cells 
that expressed IL-2 receptor [19,21]. The RNA from MT -2 cells was serially 
diluted with the RNA from peripheral blood mononuclear cells obtained 
from normal individuals (Blood supply center, Japan Red Cross Hospital, 
Tokyo, Japan) to give 11lg of RNA per sanlple and then reverse transcribed 
and amplified as described above. 
Statistical Analysis Calculations of the geometric mean ± SD and com-
parisons between values by Spearmans' rank correlation test were carried out 
with a microcomputer. Significance was defined as p < 0.05. 
RESULTS 
Plasma Levels of IL-2Ra in Patients with MF and c-ATL 
First we determined the IL-2Ra levels in sera from patients with 
MF, c-ATL, ATLA-positive asymptomatic carriers, and seronega-
tive controls by using the FS-ELISA (Fig 1). The ten patients in the 
tumor group of MF had a mean plasma IL-2Ra level of 2,352 ± 
861 U/mJ. This was significantly higher than that in the non-tu-
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Figure 2. Percentage ofIL-2Ra:-positive cells in skin lesions of nontumor 
or tumor group of patients with MF or c-ATL. IL-2Ra-positive cells were 
determined by immunoperoxidase staining and the percentage of positive 
cells to the absolute number of cells in the lesion were calculated by Kay's 
method [23,24]. The plots using dots grouped were overlaid on notched 
box-whisker plots. 
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A B 
Figure 3. Immunoperoxidase staining of sk in lesions of the tumor group of patients with MF or cATL by using anti - IL-2Ra monoclonal antibodies. A: Skin 
lesion of the patient with MF. The deposits are speckled and few positive cells are seen; these are mainly in the epidermis, with fewer in the dermis. B: Skin 
lesion of the patient with c-ATL. The deposits are dense, and numerous positive cells are seen in the dermis and epidermis, especially in the Pautrier's 
microabscess (arrow). Bar, 100 /.1- . 
mor group of MF (n = 13; 530 ± 174 U /ml). The plasma IL-2Ra 
levels were higher in the non-tumor group of c-ATL (n = 17; 
4,546 ± 1,788 U / ml) and much higher (n = 10; 17,571 ± 5,919 
U / ml) in the tumor group of c-ATL. The levels of plasma IL-2Ra 
in the non-tumor group of MF, in the group of35 ATLA-positive 
asymptomatic carriers, and in the group of 50 healthy normal con-
trols were similar to each other (data not shown). Therefore, in-
creased plasma levels of IL-2Ra appear to be useful to differentiate 
MF from c-ATL, and furthermore reflect the degree of disease pro-
gressIOn. 
Cellular IL-2Ra Levels in Skin Lesions To study the source of 
elevated levels of plasma IL-2Ra noted in the patients with MF and 
c-ATL, we compared the cellular levels of IL-2Ra in their skin 
lesions. A variable number ofIL-2Ra- positive cells were present in 
the skin lesions of patients with MF (n = 23): 12.7 ± 5.9% in the 
non-tumor group and 3.4 ± 2.3% in the tumor group (Fig 2) . Inter-
es tingly, the absolute number ofIL-2Ra - positive cells was greater 
in the tumor group than in the plague group in MF patients. Fur-
ther, the percentages of IL-2Ra- positive cells were markedly in-
creased in all patients with c-ATL (n = 27): 30.5 ± 13.4% in the 
nOll-tumor group and 62.7 ± 12.0% in the tumor group (Fig 2). 
When the positive cells in the two diseases were compared, the 
labeled deposits in skin lesions of c-ATL were seen to be denser than 
those of MF, and high variability in the positive cells was noted (Fig 
3). IL-2Ra-positive cells were not detectable in the uninvolved 
skin from all patient groups, as in the normal control epidermis (<4!a 
not shown) . 
Correlation of Plasma IL-2Ra Levels with CD25 Cell Num-
bers in the Skin Lesions In all the patients, w~ determined the 
relationship between the individual levels of plasma IL-2Ra and 
number of CD25-positive cells in the skin lesions (Fig 4). There was 
a highly significant correlation in c-ATL patients (n = 27; r = 
0.654; P < 0.0001) and in MF patients (n = 23; r = 0.537; P < 
0.01 , data not shown) . Thus, increased levels of plasma IL-2Ra 
were significantly associated with increased levels of IL-2Ra-
positive cells in skin lesions in both MF and c-ATL patients. 
Analysis of PBMC for the Cellular IL-2Ra Because plasma 
IL-2Ra levels correlated with those of skin lesions, we examined 
cell extracts of PBMC for IL-2Ra. As can be seen in Fig 5, the cell 
extract from PBMC of c-ATL patients did not show significantly 
higher levels of cell-as~ociated IL-2Ra than those of PBMC of MF 
patients. PBMC from ATLA-positive asymptomatic carriers and 
normal controls did not express cellular IL-2Ra. These findin gs 
suggested that plasma IL-2Ra levels were not linked to the PBMC 
levels of IL-2Ra in c-ATL and MF patients. 
Semiquantitation of IL-2Ra mRNA of Skin Lesions by 
DNase/RT/PCR W e next compared the expression of the IL-
2Ra gene in skin lesions (erythema or plaques), which represented 
the very early stage of MF and c-ATL. To assess IL-2Ra mRNA in 
the various skin lesions semiquantitatively, IL-2Ra DNA amplified 
by DNase/RT /PCR was semiquantitated by using a 32P-radiola-
beled system. A standard curve was generated with genomic RNA 
from the MT-2 cell line, which is HTLV-I positive and expresses 
IL-2Ra (Fig 6A,B) . 
Amplification by PCR of genomic RNA of biopsy samples from 
three c-ATL patients revealed 759 - 1015 (average, 873) MT-2 
cells containing IL-2Ra RNA per 1.0 gram of sample (Fig 6C and 
Table I) . In contrast, IL-2Ra RNA of skin biopsy samples from 
three MF patients had only a very few MT-2 cells containing IL-
2Ra RNA (range, 52- 103; Fig 6C and T able I) . Biopsy samples 
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Figure 4. Individual values of IL-2Ra-positive cell counts in skin lesions 
plotted as a sou~ce of plasma sIL-2Ra le,vels for patients with c-A TL. Corre-
lation was studied usmg the Spearman s rank test. 
with no skin lesions contained no IL-2Ra RNA. However, all skin 
samples yielded similar RT/PCR results with p-actin primer pairs 
(data not shown). 
DISCUSSION 
It is generally accepted that in CTCL malignant T cells that are 
mainly helper type T cells proliferate in the skin initially, but as the 
disease progresses it spreads to extracutaneous organs, such as lymph 
nodes, blood, and other organs [1-3] . In addition, c-ATL is a 
chronic lymphoproliferative disorder characterized by erythema, 
papules, nodules, and tumors in the skin, and sometimes it pro-
gresses to involve the blood and other organs. Further, it has been 
reported that patients wh~ were. born i~ an endemic area ofHTL V-I 
infection suffered the skm leSions with or without spontaneous 
regression, and in some of them the disease enters the blood circula-
tion [7,8,29]. Because the skin manifestations of c-ATL and CTCL 
are very similar, early identification of the subtype of CTCL has not 
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Figure 5. Analysis of peripheral blood mononuclear cells for the presence 
of cell-associated IL-2Ra in patients with nontumor or tumor group of MF 
or c-ATL. Cellular IL-2Ra levels were determined by the IL-2Ra ELISA 
using extract~ of PBMC with detergent. 
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Figure 6. Higher expression of IL-2Ra mRNA in skin lesions of patients 
with c-ATL than that of patients with MF. RNA was prepared from skin 
lesions and PCR products from both DNase/RT/PCR- and DNase/PCR-
treated samples were studied by liquid hybridization with a 32P-Iabeled 
IL-2Ra probe and size-fractionated on polyacrylamide gel electrophoresis. 
A : DNase/RT /PCR amplification of IL-2Ra RNA of MT-2 cells analyzed 
by liquid hybridization to prepare the standard curve of the IL-2Ra RNA 
amplification. The MT-2 cells, wh ich expressed IL-2Ra RNA, were 
counted and diluted to give from 128 (lalle 1) to 4 cells (lalle 6) per RNA 
amplification ofDNase/RT /PCR in the presence of a constant background 
of 1 /ig RNA of normal PBMC. Genomic RNA from PBMC stimulated 
with phytohemagglutinin for 3 d and nonstimulated PBMC were treated 
with the IL-2Ra DNase/RT /PCR and the products were used as positive 
and negative controls, respectively (PC and NC). B: Standard curve of 
amplified IL-2Ra RNA sequence to semiquantify genomic IL-2Ra RNA. 
Each data represent an average of four independent assays. C: PCR products 
of DNase/RT/PCR treated skin lesions analyzed by liquid hybridization. 
Typical results of c-ATL patients 1 (lalle c-A TL-1) , 2 (lalle c-ATL-2) , and 3 
(lalle c-ATL-3), and MF patients 2 (lalle MF-1), 5 (lalle MF-2) , and 7 (lnlle 
MF-3) are demonstrated. 
been accomplished. The data presented here show that marked dif-
ferences in the levels of IL-2Ra appear if c-ATL is separated from 
MF. The lower levels of plasma IL-2Ra seen in MF may be related 
to the lower percentage of IL-2Ra-positive cel ls seen in skin le-
sions of the patients with this disease. In contrast, patients with 
c-ATL had higher levels of IL-2Ra than those with MF. At the 
individual level, plasma IL-2Ra was significantly correlated with 
the levels of IL-2Ra- positive cells in skin lesions. As the release of 
IL-2Ra is markedly increased in cultures of HTLV-I-expressed 
cells in lIitro [15 ,16,19], it is likely that an increased amount of 
IL-2Ra can be detected in the plasma of patients with c-ATL. In this 
study, plasma IL-2Ra levels were significantly correlated with the 
number of IL-2Ra-positive cells in skin lesions of patients with 
both MF and c-ATL. However, there was no significant difference 
in IL-2Ra levels in PBMC between the patients with these two 
diseases. These findings suggest that the IL-2Ra-positive cells in 
skin lesions of both MF and c-ATL are a likely source of the IL-2Ra 
in the circulation . 
Of great interest was the difference in the percentage of IL-2Ra 
(CD25 antigen) - positive cells between the tumor group of mycosis 
fungoides and the tumor group of c-ATL in each ten samples. The 
difference of measuring values between the two diagnostic groups 
was greatest among the measuring parameters employed in this 
study. Most of the IL-2Ra-positive cells in skin lesions of c-ATL 
contained larger amounts of IL-2Ra than do IL-2Ra- positive cells 
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Table I. Determination of the IL-2Ra RNA Copy Number 
Index in Skin Lesions of Patients with MF and c-ATL by 
Densitometric Detection" 
Patient Data IL-2Ra Copy Number 
Index in Skin 
Patient Number Age/Sex Skin Lesions Lesions 
Patients with MF 
1 58/Mb Plaque 102.3 
2 57/M Plaque 92.9 
3 32/M Plaque 53.8 
4 36/M Plaque 62.5 
5 61/Fb Plaque 73.4 
6 36/F Erythema 52.4 
7 50/M Erythema 56.5 
Patients with c-ATL 
1 73/F Papules 1015.7 
2 70/M Papules 971.6 
3 57/F Papules 836.7 
4 5l/M Papules 782.2 
5 62/F Erythema 795.4 
Healthy controls 39.8 
• IL-2Ra copy number was expressed as mean of three separate experiments and 
calculated as follows: (MT -2 cell number ofIL-2Ra RNA detected by densitometry as 
described in Fig 7)/(1.0 g of biopsied skin). 
! M, male; F, female . 
of MF. suggesting that IL-2Ra - positive cells in skin lesions of 
c-ATL may be c-ATL cells. The ATL cells usually seen as strong 
IL-2Ra-positive cells have been shown to release mediators that 
were implicated as pathogenic [30]. T-cell lines express HTLV -I. 
and leukemia cells from patients with A TL expressed 5 to 10 times 
more IL-2Ra on their cell surface and released more IL-2Ra in 
soluble form into culture supernatants than normal activated T cells 
[19.31]. This constitutive IL-2Ra expression is thought to result 
from the activation of HTLV-I Tax. which activates the IL-2Ra 
gene through the KB element by trans-activation of transcription. 
which leads to increased and non-regulated IL-2Ra expression 
[32.33] followed by the release oflarge amounts of soluble protein. 
Thus. the percentage ofIL-2Ra - positive cells in skin lesions seems 
to be of diagnostic significance between tumor groups of MF and 
c-ATL. Further. the higher percentage of IL-2Ra - positive cells 
may be related- to the higher levels of plasma IL-2Ra in c-ATL. 
When we measured plasma IL-2Ra levels in 16 cases of c-ATL in 
the very early stage without ATL cells in the circulation (Table I) 
we detected clearly elevated levels of IL-2Ra (average. 8890 U j 
ml). In the study. the levels ofIL-2Ra in AT LA-positive asympto-
matic carriers were much lower and more similar to those in normal 
individuals. Moreover. detection of IL-2Ra in the plasma is more 
useful than determination ofIL-2Ra levels in the skin lesion. as the 
high titer of IL-2Ra suggests the existence of c-ATL: Actually we 
could not detect monoclonal integration of HTLV -I in these very 
early stages of c-ATL by using genomic DNA from PBMC, al-
though its detection rate will increase when using skin biopsy sam-
ples. Therefore. measuring plasma IL-2Ra levels would seem to be 
useful for making an early diagnosis of c-ATL and MF. 
Furthermore. elevated levels of plasma IL-2Ra were associated 
with more advanced stages of MF and c-ATL. These observations 
taken together support the view that increased skin IL-2Ra levels 
may be related to the stages of CTCL. However. sequential studies 
of patients during the course of the diseases are critical to determine 
if there is a direct correlation between IL-2Ra levels and progres-
sion of the diseases. 
Elevation of plasma IL-2Ra is not restricted to patients with 
c-ATL or MF. Other hematologic malignancies have also been 
reported to have elevated plasma levels [34,35]. In patients 'with 
HTLV-I-associated myelopathy the plasma IL-2Ra levels in-
creased moderately [20]. Lately, Bernengo et al [36] reported in-
creased serum levels of s1L-2Ra in patients with Sezary syndrome 
and mycosis fungoides . There was no information on patient states 
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on individual levels; however. sIL-2R correlated with the clinical 
course of Sezary syndrome. Further, we observed IL-2R levels by 
various parameters in both non-tumor group and tumor group of 
MF. The levels in c-ATL were higher than those found in other l 
diseases. 
Because antibody titer is not reflective of the stage of HTL V -I - I 
induced diseases. seropositivity of HTL V -I infections were usually 
checked. All 27 tested patients with c-ATL demonstrated seroposi-
tive for HTLV-I and 23 cases of MF were seronegative. However. 
Zucker-Franklin et al [37] previously reported a small percentage of 
patients with MF have antibodies to HTLV-1. There has also been 
reported a MF patient seropositive for HTL V -I in the southern part 
of Japan (Katahira Y et ai, personal communications) . Conversely, 
Shimoyama et al [38] observed an ATL case with skin manifestation 
that is not associated with HTL V -I antibodies. Thus, IL-2Ra levels 
appear to exhibit diagnostic values of differentiation between MF 
and c-ATL. 
Further, there was the highly significant difference of IL-2Ra 
RNA levels in skin lesions of very early stages of patients with 
c-ATL and MF. revealed by the DNasejRTjPCR method. The 
amplified IL-2Ra PeR-product was significantly increased in all 
five patients of c-ATL. However, IL-2Ra mRNA was barely de- • 
tectable in seven patients with MF. IL-2Ra mRNA was not de-
tected by the PCR in control skin sites with no lesions. All five 
patients with c-ATL demonstrated increased plasma IL-2Ra levels 
(average. 4.957 U jml) whereas the seven MF patients did not (aver-
age 452 U jml). Thus. the results of this study suggest that the levels 
of IL-2Ra gene expression determined by DNasejRTjPCR and 
generation of the protein molecule of plasma IL-2Ra will also pro-
vide information for detecting both MF and c-ATL at the patient's 
initial visit. 
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ANNOUNCEMENT 
A two-day international conference "Pharmacologic Intervention in the Ageing Process" will 
be convened by Prof. A. Kligman, University of Pennsylvania, in London, September 26-27, 
1994. 
For further details, please contact either Jackie Ford or John Jennings, MAIC Ltd, Croxted 
Mews, 286A-288 Croxted Road, London SE24 9BY, UK. Tel, ++44 (0) 81-671-7521; Fax, 
++44 (0) 81-671-7327. 
